论文部分内容阅读
目的 评价CPE(卡铂、顺铂、足叶乙甙)和CE(卡铂、足叶乙甙)方案治疗小细胞肺癌(SCLC)的疗效和毒性。方法 应用CPE和CE方案治疗32例SCLC患者,每组16例,CPE组和CE组中的复治病例分别为10例和7例。结果 CPE组和CE组的有效率分别为81.3%(13/16)和87.5%(14/16)(P>0.05)。CPE组与CE组中的复治病例有效率分别为60%(6/10)和42.9%(3/7)(P<0.05)。CPE组与CE组的骨髓抑制率分别为71.9%和93.8%(P<0.05)。两组间其它毒性反应差异无显著性(P>0.05)。结论 CPE方案治疗SCLC的疗效与CE方案相近,但CPE的骨髓抑制明显较CE轻;CPE对复治病例的疗效优于CE。
Objectives To evaluate the efficacy and toxicity of CPE (carboplatin, cisplatin, etoposide) and CE (carboplatin, etoposide) regimens in the treatment of small cell lung cancer (SCLC). Methods Thirty-two patients with SCLC were treated with CPE and CE regimens. There were 16 patients in each group. Retreatment cases in CPE and CE groups were 10 and 7 cases respectively. Results The effective rates of CPE and CE were 81.3% (13/16) and 87.5% (14/16) respectively (P>0.05). The retreatment rates in the CPE and CE groups were 60% (6/10) and 42.9% (3/7), respectively (P<0.05). The myelosuppression rates of CPE and CE groups were 71.9% and 93.8%, respectively (P<0.05). There was no significant difference in other toxicities between the two groups (P>0.05). Conclusions The efficacy of CPE regimen in the treatment of SCLC is similar to that of the CE regimen, but the bone marrow suppression in CPE is significantly lower than that in CE; CPE is superior to CE in retreatment.